Phase IIINeuropeptide
Compound 61610
Formula Pending
Molecular Mass
N/A
CAS Registry
AUTO-061610
Risk Class
LOW
Last Audit
May 5, 2108
Research Abstract
Neuropeptide candidate engineered for metabolic regulation initiatives with automated dossier coverage.
Compound 61610 is a neuropeptide asset inside neuropeptide innovation track initiatives, optimized for metabolic regulation and cardiometabolic recovery.
The dossier currently sits in phase iii with a low risk rating, meaning it is cleared for baseline monitoring protocols.
Supply records cite CAS AUTO-061610 with updates logged 2108-05-05.
Acquisition Protocol
Authorized research personnel may request deployment of this compound for laboratory analysis.
Primary Vectors
Metabolic regulationCardiometabolic recovery
Nomenclature
CX-61610Neuropeptide Program 61610
Reference Material
- [1] Anubis Compound Registry • CAS AUTO-061610
- [2] Operations Pulse • Neuropeptide innovation track
- [3] Risk Governance Ledger • LOW clearance for COMPOUND-61610